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Abstract
The current research work encompasses the development, characterization, and evaluation of self-assembled phospholipidic
nano-mixed miceller system (SPNMS) of a poorly soluble BCS Class IV xanthone bioactive, mangiferin (Mgf) functionalized
with co-delivery of vitamin E TPGS. Systematic optimization using I-optimal design yielded self-assembled phospholipidic
nano-micelles with a particle size of < 60 nm and > 80% of drug release in 15 min. The cytotoxicity and cellular uptake studies
performed using MCF-7 and MDA-MB-231 cell lines demonstrated greater kill and faster cellular uptake. The ex vivo intestinal
permeability revealed higher lymphatic uptake, while in situ perfusion and in vivo pharmacokinetic studies indicated nearly 6.6-
and 3.0-folds augmentation in permeability and bioavailability of Mgf. In a nutshell, vitamin E functionalized SPNMS of Mgf
improved the biopharmaceutical performance of Mgf in rats for enhanced anticancer potency.
Keywords Breast cancer .Quality bydesign (QbD) .Mangiferin .VitaminETPGSnanomicelles . Self-assembledphospholipidic
nano-mixedmiceller system (SPNMS) . Pharmacokinetics . Bioavailability . P-gp efflux . Cellular uptake
Introduction
Mangiferin (Mgf), a naturally produced polyphenol molecule
possessing four hydroxyl groups, is an efficient antioxidant
for free radical chain termination [1]. Mgf shows potential
cytotoxicity effects on cancer cells and may even induce apo-
ptosis by inhibiting and suppressing nuclear factor kappa B
(NF-kB) and NF-κB-inducing kinase [2, 3]. Several literature
[3, 4] also report Mgf-induced apoptosis, and tumorigenesis
through altered gene expression [5–7], especially using Bcl-2
and Bax. Definitive activity of this bioactive phytochemical
has also been documented on HL-60 cells programmed cell
death, ascribed to suppression of Bcl-xL and XIAP expression
and inhibition of the NF-kB pathway [8].
Despite being a very potent antioxidant molecule, Mgf
exhibits very low and variable bioavailability (i.e., 1.5 to
5%), owing principally to limited aqueous oral solubility
(i.e., 0.1 to 0.3 mg/mL) and poor lipophilicity (i.e., log P
of − 0.56), extensive P-gp efflux, high first-pass effect,
and considerable metabolism by gut Cytochrome P-450
enzymes [9–14]. By virtue of its low aqueous solubility
and lipophilicity, Mgf can be safely regarded as a BCS
class IV agent.
Owing to the aforementioned challenges [15], several sci-
entists have attempted to enhance the oral bioavailability of
Mgf by formulating its solid dispersions [16], β-cyclodextrin
complexes [17, 18], phospholipid complexes [19], and spray-
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dried encapsulation [5]. None of the conventional formula-
tions, therefore, is considered to be highly satisfactory in
completely surmounting the multifactorial issues of solubility,
lipophilicity, and eventually the bioavailability of Mgf.
However, the increase of Mfg bioavailability compared to
the plain drug has previously been observed with nanostruc-
tured lipidic carriers (NLCs) carrying Mfg and Mfg-
phospholipid complex [20], indicating safety towards Caco-
2 cells with enhanced intestinal permeation parameters. Xiao
and associates elucidated the augmentation in in vitro antitu-
mor activity of Mfg conferred by Mfg loaded magnetic poly-
meric microspheres [21].
The phospholipid systems have lately been explored for
enhancing the biopharmaceutical performance and therapeutic
efficacy of several bioactives exhibiting poor hydrophilicity
and lipophilicity [20]. As phospholipids constitute major part
of the bio-membrane, these hold good biocompatibility, while
acting as a carrier for delivering drugs across the biological
barriers. The amphiphilic nature of phospholipids is docu-
mented to enhance solubility and permeability of the drugs,
thus improving their oral biopharmaceutical performance
[22]. Other stellar merits of phospholipidic formulations in-
clude ease of preparation, along with high drug loading capac-
ity and long-term stability. Further, the employed emulgents
and co-emulgents lead to complete micellization of the system
and thus solubilizing the BCS class IV bioactive, leading
eventually to improved absorption potential and thus better
bioavailability.
Self-assembled Phospholipidic Nano Mixed Miceller
System (SPNMS), in this regard, hold tremendous market
potential due to ease in their manufacturing, higher cost-effec-
tiveness, improved efficacy, and higher scalability [23]. This
is the first report of its own kind that offers an insight to the use
of SPNMS for improving the in vitro breast cancer cytotoxic-
ity and augmenting the biopharmaceutical attributes of Mgf.
Lately, SPNMS have demonstrated considerable potential
to enhance the oral bioavailability of anticancer bioactives
owing to their ability to circumvent the major hiccups faced
by the latter [24–26]. Composed of lipidic constituents, water-
insoluble (with HLB < 12; used in 0–20 parts) and water-
soluble (with HLB > 12; used in 30–80 parts) emulgents,
coemulgents, and cosolvents, these systems are known to pro-
duce ultrafine micelles (i.e., < 50 nm in size) in the gastroin-
testinal (GI) fluids [27]. Hence, SPNMS have been considered
as one of the most promising technologies for a vast diversity
of drugs [28]. The key feature of such systems is their ability
to incorporate drugs exhibiting values of low partition coeffi-
cient [29, 30]. Vitamin E D-α-tocopheryl polyethylene glycol
1000 succinate (TPGS) has been widely used as an emulsifier
in nanoparticle formulation of anticancer drugs leading to high
drug encapsulation and substantially high cellular uptake by
cancer [31]. It also has a dual role, one as a bioactive and the
other as a P-gp inhibitor that can block the cancer cell action of
pumping drugs outside of cells and can enhance the anticancer
effect [32, 33].
Mixture designs are highly recommended in a delivery
system with multiple excipients, wherein the characteristics
of the finished product usually depend on the proportion of
each substance present, but not on each quantity. Also, opti-
mal designs are preferred when the nature of factor-response
relationship is either unknown or is obscure [34]. D-optimal
designs, based on the principle of minimization of variance
and covariance of parameters, require correct model(s) to be
postulated, variable space to be defined, and number of design
points to be so chosen that determines the model coefficients
with maximum possible efficiency [35].
Attempts were, therefore, made in the current studies for
improving the drug loading potential, enhancing dissolution
rate, and augmenting the oral bioavailability of Mgf
employing systematically prepared functional SPNMS with
co-delivery of TPGS, and evaluating these extensively for
their biopharmaceutical attributes. Further, its anticancer po-
tential and cellular uptake in mammary adenocarcinoma cell
lines (MDA-MB-231 and MCF-7) have also been investigat-
ed. Also, toxicity of the developed and blank formulations
was evaluated by excising out all the vital organs followed
by their histopathological examination. The present research
article offers an insight to use the functionalized SPNMS for
improving the biopharmaceutical attributes ofMgf. In vitro, in
situ, and in vivo studies carried out on the formulations proved
these nanostructures to be highly superior to the pure
bioactive.
Materials and methods
Mgf was obtained from M/s International Association on
Mangiferin Research (IAMR), Nanning, Guangxi, China.
Vitamin E TPGS and poly(ethylene glycol) 200 (PEG 200)
were purchased from M/s Sigma-Aldrich, Chemicals Pvt.
Ltd., Mumbai, India. Phospholipid 90G was provided as ex-
gratis from Lipoid GmbH, Germany. Empty gelatin capsule
shells (size 00) were supplied as gift samples by M/s ACG
Associated Capsules Pvt. Ltd., Mumbai.
Identifying quality target product profile and critical
quality attributes
As the first and foremost step, quality target product profile
(QTPP) was embarked upon as the formulation objectives
(Supplementary Table 1) to achieve the maximal therapeutic
efficacy for enhancing the bioavailability of Mgf. Valid justi-
fication(s) were documented for choosing the apt critical qual-
ity attributes (CQAs) to subsequently formulate SPNMS of
Mgf (Supplementary Table 2), using the systematic approach
of Quality by Design (QbD).
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Risk assessment studies
Risk assessment studies were performed to identify, analyze,
and assess the possible interaction(s) among Mgf, excipients,
and other process parameters. Ishikawa fishbone cause-and-
affect diagram was constructed and failure mode effect anal-
ysis (FMEA) was carried out in order to earmark the critical
material attributes (CMAs) and/or critical process parameters
(CPPs) for SPNMS of Mgf [36].
Equilibrium solubility studies
Solubility studies for Mgf were carried out for 72 h at 37 ±
1 °C in a water bath by adding an excess amount of drug in
various water-soluble emulgents, viz. Acconon CC-6,
Cremophor RH40, Cremophor EL, Vitamin E TPGS,
Labrafil M1944, Labrasol, Tween 80 and Tween 40.
Cosolvents employed included Transcutol HP, PEG 200,
and propylene glycol. Aliquots of the filtrate were suitably
diluted with methanol and analyzed using the HPTLC
method previously reported by the authors at a λmax of
262 nm [37].
Construction of pseudo-ternary phase diagrams
Phase titration studies were conducted on Phospholipid 90G,
Vitamin E TPGS (emulgents), and PEG 200 (cosolvent) as the
surfactant mixture (Smix; in the ratio 1:0,1:1,2:1, and 3:1) in
the varying ratios, ranging from 1 to 9, were titratedwith water
at 37 °C to attain the maximal emulsification region [38].
Pseudo-ternary diagrams were constructed using the PCP
Disso software ver 3.0 (M/s Pune College of Pharmacy,
Pune, India).
Preparation of Mgf SPNMS
SPNMS of Mgf (dose equivalent to 30 mg) were prepared
by employing the self-assembly method [39]. Mgf was
complexed with Phospholipid 90G (1:1) as per the already
developed method [20]. Subsequently, addition of vitamin
E TPGS and PEG 200 in ethanolic mixture was carried out
using magnetic stirrer at room temperature. Afterwards,
butylated hydroxyl toluene (BHT) 0.2% w/w of the total
lipid was dissolved in the above alcoholic solution. The
aqueous phase containing phosphate buffer saline (pH
7.4), sodium metabisulphite (0.5% w/w), and 0.01% of
Triton X-100 was poured into the organic phase in a
streamlined manner with continuous stirring at 2000 rpm.
The dispersion was stirred for 5–10 min after complete
addition of the aqueous phase [40, 41].
QbD-based formulation optimization studies
For systematic optimization of Mgf-SPNMS formulations, an
I-optimal mixture design matrix was constructed with 16 runs
including five replicates, using the Design Expert® software
version 9.0.1 (M/s Stat-Ease, Minneapolis, USA) in order to
optimize the amounts of CMAs viz. Phospholipid 90G (X1),
vitamin E TPGS (X2), and PEG 200 (X3). Various levels of
CMAs were deduced from the pseudoternary phase diagrams.
Supplementary Table 3 displays the design matrix for all the
prepared formulations containing 30 mg of Mgf. All the pre-
pared formulations were evaluated for Q15, %DE, Dnm, and
Temul as the CQAs.
QbD-enabled data analysis and validation
In order to correlate CMAswith CQAs, multiple linear regres-
sion analysis (MLRA) was applied to get the coefficients of
polynomial equations employing [35]. Various model param-
eters like p value, coefficient of correlation (R), and predicted
error sum of squares (PRESS) were analyzed. Besides, 3D-
response surface and 2-D contour plots were generated to
relate CQAs with CMAs. Further, optimum solution was lo-
cated by numerical optimization using maximization of the
desirability function value, close to unity.
Characterization of SPNMS
Self-emulsification time (Temul)
A single dose of the prepared Mgf-SPNMS (1 g) was poured
drop-wise in 250 mL of 0.1 N HCl, while stirring at 50 rpm,
using a USP XXXI Apparatus II (DS 8000, M/s Lab India
Instruments, Mumbai, India) at ambient temperature. The
emulsification time was assessed visually and medium was
observed for self-emulsification in triplicate.
Globule size (Dnm) and zeta potential
SPNMSwere prepared by dilution (1 mL) in triplicate forDnm
and zeta potential analysis employing Zetasizer ZS 90, (M/s
Malvern Instruments, Worcestershire, UK [42].
In vitro dissolution studies
The dialysis bag method was employed to study the in vitro
release of Mgf from Mgf-SPNMS. Dissolution studies on the
SPNMS formulation (n = 6), incorporated in hard gelatin cap-
sules, were conducted in 250 mL of 0.01 N HCl containing
0.5% SLS using USP 31 Type II Apparatus, stirred at 50 rpm
at ambient temperature. An aliquot of 5 mL each of the disso-
lution medium was withdrawn periodically, and replaced with
fresh medium to maintain the sink conditions; analysis of Mgf
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was carried out at a λmax of 262 nm using the HPTLC tech-
nique. From the drug release profile, CQAs like drug release
in 15 min (Rel15min), mean dissolution time (MDT), and dis-
solution efficiency (DE) were calculated.
Transmission electron microscopy (TEM)
The formulation was observed for microscopy by placing it on
a copper grid, stained with phosphotungstic solution (1%) for
30 s (JEM-2100 F, M/s Jeol, Tokyo, Japan).
Ex vivo permeation studies
The method has already been elaborated in one of the pub-
lished works reported previously by our group [43]. The per-
meation studies were carried out by excising out the small
intestine of sacrificed rats, washed with Kreb’s Ringer
Buffer (KRB). The jejunum portion was everted on a glass
rod after ligation with a thread and equilibrated subsequently
in thermoregulated KRB solution. An accurately weighed
amount of pure Mgf and optimized Mgf SPNMS (30 mg
Mgf) were placed in bath medium outside the gut sac. From
the gut sac, aliquots of samples (of 1 mL each) were period-
ically withdrawn and analyzed using HPTLC to discern the
percentage of drug permeated in 45 min (Perm45min).
MCF-7 and MDA-MB-231 cell-based testing
Cell culture
Human breast adenocarcinoma cells (MCF-7) were obtained
from the University of Manchester, UK, and MDA-MB-231
cell lines were purchased from the European Collection of
Authenticated Cell Cultures (ECACC), Public Health
England, Salisbury, England. To grow MCF-7 cell lines,
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) and
tissue culture flasks were employed (75 cm2) and maintained
constantly in an incubator at 37 °C with 5% CO2. The culture
was trypsinized using 1% trypsin, once the cells were 90%
confluent. Similarly, to grow MDA-MB-231 cells, L-15
Medium (Leibovitz) was employed at 37 °C without CO2.
Cell viability assay
The concentration- and time-dependent cell viability assay of
Mgf, blank SPNMS, and Mgf SPNMS were assessed on
MCF-7 and MDA-MB-231 cell lines using PrestoBlue cell
viability reagent (Invitrogen, USA). Briefly, an aliquot of
100 μL of medium containing 1000 cells per well was seeded
in 96-well cell culture plates (Costars, Corning Inc., NY,
USA) and incubated for a period of 24 h. The medium was
replaced with 90μL of different concentrations (10–1000 nM)
of the said formulations. Cells were treated with the
formulations in separate culture plates before incubating for
24, 48, and 72 h at 37 °C on 5% CO2. Before calculating the
fluorescence, 10 μL PrestoBlue was added 1 h before and the
culture plates were incubated at the end of respective time
interval [39, 44]. Cell viability was determined using fluores-
cence measurement at excitation and emission wavelengths of
560 and 590 nm, respectively, and expressed as percentage
normalized to untreated controlled cells.
Qualitative and quantitative cellular uptake
Investigations for qualitative cellular uptake were conducted
by fluorescence microscopy on MCF-7 and MDA-MB-231
cell lines employing Rhodamine 123 (Rh-123) as a tracker
dye, loaded in SPNMS [45]. Cells (1 × 105 per well), both
for MCF-7 and MDA-MB-231, were plated onto glass cover
slips in DMEM and L-15 media, respectively, and allowed to
adhere for overnight. Once adhered, the cells were treated with
0.064 μMRh-123-loaded SPNMS for 15 min to 4 h separate-
ly at 37 °C. Pre-warmed PBS was used to wash cells thrice,
subsequently fixed for 20 min at room temperature using 4%
(v/v) paraformaldehyde. Cells adhering to microscopic slides
were washed thrice with PBS prior to mounting with
Vectashield®, a mounting medium containing 300 nM of
DAPI (4′,6-diamidino-2-phenylindole), a fluorescent stain
for nucleus staining. Cells were imaged on a modified cell
observer imaging system (Zeiss EC Plan-Neofluar × 40/1.3
oil objective). Rh-123 and DAPI were imaged using a GFP/
DAPI filter set with Ex/Em wavelength of 450–490 nm/500–
550 nm and 335–383 nm/420–470 nm, respectively. Analysis
of the images was carried out using the Zeiss ZEN desk im-
aging software. For quantitative measurement, cells (1 × 105)
were seeded in each well of six-well plate and incubated for
overnight. Rh-123-loaded SPNMS (100 μg/mL) were added
to each well of the six-well plate and incubated for different
time intervals, in a manner similar to qualitative measurement
[44, 46]. After respective time points, medium containing
SPNMS was removed and cells were trypsinized and re-
suspended in PBS for immediate flowcytometry analysis.
Rh-123 signals were detected in FL-1 channel of BD
FACSAria flowcytometer. A total of 10,000 events were proc-
essed and data were analyzed on Flowing version 2.5.1
(PertuuTerho, Turku Centre for Biotechnology, University of
Turko, Finland).
P-gp efflux assay
Overexpression of P-gp in MCF-7 and MDA-MB-231 cells
is well-documented in literature [47–49]. P-gp efflux pump
does not let anticancer drugs to accumulate within the cell
by effluxing it time and again, thereby preventing their
cytotoxic or apoptotic effects on cancer cells. For evaluat-
ing the P-gp efflux, the multi-drug resistance dye efflux
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assay kit (Chemicon International, USA) was employed in
which the MCF-7 and MDA-MB-231 cells (2.5 × 105)
were treated with Rh-123 and DiOC2 dyes, with or without
vinblastine. To assess the inhibitory activity of SPNMS on
MDR1 transporters, these were incubated with Rh-123
alone, Rh-123 with SPNMS, and Rh-123 with vinblastine
at 37 °C, along with Rh-123 at 4 °C. Likewise, to estimate
the potential of the developed SPNMS formulation for
blocking the activity of BCRP transporters, DiOC2 dye
was employed. On similar heels, MCF-7 and MDA-MB-
231 cells (2.5 × 105) were incubated with DiOC2 alone,
DiOC2 with SPNMS, and DiOC2 with vinblastine at
37 °C, along with DiOC2 at 4 °C. The fluorescence inten-
sity was measured in a TECAN fluorescence microplate
reader at an excitation wavelength of 485 nm and an emis-
sion wavelength of 530 nm [50].
Animal Studies
Animals
Animal studies were carried out on Sprague Dawley (SD) rats
in bred and housed in Central Animal House, Panjab
University, Chandigarh, India. Standard housing conditions
were maintained and animals were kept on regular solid feed
and water ad libitum. The animal experiments were performed
in accordance with the recommendations of the committee for
the purpose of control and supervision of experiments on an-
imals (CPSCEA), India. The study protocol was approved by
the institutional animal ethics committee (IAEC) of Panjab
University, Chandigarh (Protocol no. 578/IAEC dated 1/08/
2016).
Intestinal permeation study of Mgf: Confocal laser scanning
microscopy
Small intestine from the abdominal cavity of SD rats (n =
3) was excised after sacrificing the rat and flushed it with
0.9% sodium chloride solution to remove any traces of
feces and blood. Rh-123-loaded SPNMS formulation was
introduced in the intestine and kept for 2 h [51]. Microm
HM 525 U Cryostat, Thermo Fisher Scientific, USA, was
employed for the study with a microtome, i.e., a slicer and
a freezer. The intestine specimen was placed on a metal
tissue disc, embedded in OCT, consisting of polyethylene
glycol and polyvinyl alcohol, secured in a chuck, and fro-
zen (− 20 to − 30 °C) rapidly to slice up to 10-μm sections.
The section was placed on a glass slide mounted with glyc-
erol, covered with a cover slip to capture the image with
the confocal microscope (CLSM) (NIKON C2 PLUS, soft-
ware IVIS Elements AR).
In situ intestinal perfusion
The in situ perfusion studies were performed as per the pro-
cedure previously reported in literature [52]. Briefly, unisex
SD rats were put on fasting overnight and divided into two
groups with three animals per group, viz. plain Mgf and Mgf-
SPNMS. Anesthetized animals were slit open at their abdo-
men and their jejunum was incised at the upper and lower
parts for 4 cm to perfuse KRB. An aliquot of perfusate
(1 mL each) was withdrawn periodically and the content of
Mgf was analyzed using the HPTLC analysis at 262 nm [37].
Various absorption and permeability parameters were calcu-
lated as per the details mentioned in Supplementary
Section 2A.
In vivo pharmacokinetic studies
In vivo pharmacokinetic studies were conducted by sparse
sampling designed experiment. The formulations were admin-
istered through oral gavage on two groups of rats (n = 60).
Within each group, five subgroups were designated (5 × 6 =
30 animals were employed in one group) and from one animal
maximum two blood samples were withdrawn during the en-
tire study alternating between left and right eyes. Group I was
administered plain Mgf solution and Group II was given Mgf-
SPNMS containing Mgf equivalent to 30mg/Kg [39]. The
animals were anesthetized employing isoflurane, and the
blood (200 μL) was withdrawn from the retro-orbital plexus
of rats at 0.5, 1, 2, 3, 6, 12, 18, 24, and 36 h, in heparin-coated
micro-centrifuge tubes.
Further, plasma was harvested by centrifugation at
10,000 rpm (559 g) for 5 min and analyzed for Mgf using
the previously reported and validated HPTLC method [37].
The data were analyzed by non-compartmental and compart-
mental pharmacokinetic modeling approaches using the
WinNonlin software, version 5.0 (M/s Thermo Scientific,
USA) [53]. Statistical tests like one-way/two-way ANOVA
followed by post hoc multiple comparison tests, and
Student’s independent t test has been applied wherever
applicable.
Histopathology and hematological studies
A total of 12 SD female rats were divided into four groups,
with three animals in each group. Plain Mgf, blank SPNMS,
and Mgf-SPNMS (containing an equivalent amount of
30 mg/kg Mgf) were administered three times per week for
4 weeks in total by oral gavage with suitable intubation can-
nula. Animals of control group were administered normal sa-
line. At the end of the study, the animals were euthanized by
isoflurane. All the vital organs were excised, and fixed in 10%
formalin for a minimum period of 24 h. Further, the tissues
were passed through a cascade of steps like dehydration with
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increasing score of ethyl alcohol, clearing in xylol and mount-
ing in molten paraplast at 58–62 °C [54], staining of sections of
5μmwith hematoxylin and eosin stain (H&E), and subsequent
observation for any histopathological change(s) vis-à-vis con-
trol under a light microscope. The further procedural details of
the histopathology are in Supplementary Section 2B.
Further, after anesthetizing the rats, the blood was collected
into 10-ml citrate-phosphate-dextrose anticoagulant vacuum
tubes (Haematologic Technologies Inc., USA) by cardiac
puncture. Harvested blood was centrifuged (2200×g, 10 min
at 4 °C), and the plasma and buffy coat were removed by
aspiration. The thin smear slide of the blood from each group
was observed under light microscopy. The further procedural
details of the hematology are in Supplementary Section 2C.
Results and discussion
Risk Assessment Studies
Supplementary Fig. 1 displayed the Ishikawa diagram with
the aim to identify CQAs of Mgf-SPNMS, constructed with
the help of the Minitab 16 software; FMEA (Supplementary
Table 4) was carried out to estimate the risk(s) caused by
selected MAs and/or PPs.
Preliminary Screening
The equilibrium solubility studies revealed that among the
surfactants, maximum solubilized fraction of Mgf, i.e.,
17.64 mg.mL−1, was observed in vitamin E TPGS
(Supplementary Fig. 2A). Among the cosolvents, the highest
solubility of Mgf was observed in PEG 200 (i.e.,
10.23 mg.mL−1) (Supplementary Fig. 2B). For better solubi-
lization of the drug in SPNMS, proper selection of emulgent
and cosolvents is quite imperative, and their emulsification
properties are based upon the reduction in energy required to
emulsify [55]. The cosolvents further help in reduction of
interfacial tension and formation of very fine droplets [56].
Further, it was evident from the ternary diagrams that the
Smix (3:1) formed a wider nanoemulsion region, as illustrated
in Supplementary Fig. 3(A–D).
Factor screening studies
Pareto charts and half-normal plots revealed the effect of
MAs/PPs on the studied CQAs (i.e., Rel15min, Dnm, and
Temul) divulging that vitamin E TPGS (emulgent) and PEG
200 (cosolvent) were highly influential, as their effect was
beyond t value and Bonferroni line limits (Supplementary
Fig. 4(A–F)). Emulgent was found to exert a notable effect
on the Rel15min, Dnm, and Temul, while coemulgent and
cosolvent had higher influence on Dnm, and Temul.
Nevertheless, the other employed factors like type of mixing,
stirring speed, stirring time, and temperature were kept as
constant for further studies, as these caused only a trifling
effect on the studied CQAs.
QbD-based model development and response surface
analysis
The MLRA technique was employed to build second-
order quadratic model and the coefficients for each of
the CQAs [57] (Eq. 1). Excellent fit of the data was quite
apparent from high values of coefficient of correlation,
ranging between 0.965 and 0.998 (p < 0.001 in all the
cases).
Y ¼ β1X 1 þ β2X 2 þ β3X 3 þ β4X 1X 2 þ β5X 1X 3
þ β6X 2X 3 þ β7X 1X 2X 3 þ β8X 1X 2 X 1−X 2ð Þ
þ β9X 1X 3 X 1−X 3ð Þ þ β10X 2X 3 X 2−X 3ð Þ ð1Þ
where, Y is the response variable, β1 to β4 are the coeffi-
cients of linear model terms, β5 to β7 are the coefficients
of quadratic model terms, β8 to β10 are the coefficients of
cubic model terms with added interaction terms, while X1,
X2, and X3 represent the factors employed (Supplementary
Table 5).
The generated response surface plots helped in inclu-
sive understanding of the impact of CMAs on the studied
CQAs. The 3D-response surface plot in Fig. 1a indicates
combined influence of all the CMAs, i.e., Phospholipid
90G, vitamin E TPGS, and PEG 200 on the studied
CQA, i.e., globule size. A trivial increase in Dnm was
observed at the high levels of Phospholipid 90G and in-
termediate levels of vitamin E TPGS, while a decreasing
trend was noticed at the high levels of PEG 200. The
minimum value for globule size was noticeable at the
intermediate to high levels of vitamin E TPGS, and the
intermediate levels of PEG 200, respectively. Smaller
globule size, as is well-documented, is highly desirable
for quicker absorption of drug into the systemic circula-
tion [58].
Figure 1b depicts an umbrella-like 3D-response surface
plot, portraying the maximum value of Rel15min at the
intermediate levels of Phospholipid 90G, vitamin E
TPGS, and PEG 200. The plot shows a sharp rise in
Rel15min values at the intermediate levels of PEG 200
and vitamin E TPGS [59], indicating the highest values
of Rel15min. Phospholipid 90G showed a negative effect
on the release behavior, which could be attributed to its
drug solubilization potential.
Figure 1c represents the 3D diagrammatic depiction of the
positive influence of intermediate levels of Phospholipid 90G
and vitamin E TPGS on the MDT values. However, on
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increasing levels of PEG 200, the values of MDT exhibited a
declining trend. This unraveled a remarkable influence of
lipids and surfactant onMDT, while the cosolvent had varying
influence from negligible to high.
The 3D-response surface plot (Fig. 1d) exhibits a sharp
decline with increase in the concentration of Phospholipid
90G and PEG 200, while vitamin E TPGS shows increase in
the values of DE at its high level. Minimum value of DE was
observed at the intermediate levels of vitamin E TPGS and
PEG 200, and low levels of Phospholipid 90G.
Figure 1e shows negligible influence of all the constit-
uents on the values of Temul, thus delineating the absence of
interaction effect among them. At all the levels of the stud-
ied constituents, no significant change was observed
(p > 0.05).
Figure 1f shows that at the lower levels of Phospholipid
90G, Perm45min values were observed to be maximal, follow-
ed by decreasing trend with increased levels of vitamin E
TPGS. On the contrary, PEG 200 shows declining effect on
Perm45min values. A hump-shaped curve in the 3D plot was
observed at the intermediate levels of Phospholipid 90 G,
indicating high values of Perm45min. This clearly supported
the fact that Phospholipid 90G helps in faster permeation of
drug across the GI tract into the systemic circulation.
Figure 1g exhibit declining values of zeta potential at in-
creasing concentrations of Phospholipid 90G and PEG 200,
while vitamin E TPGS shows increase in the zeta potential
values at higher levels, followed by a dip at the highest levels.
Higher values of zeta potential, required for maintaining phys-
ical stability of the nanoformulations, were observed at low to
intermediate levels of all the constituents.
Characterization of the prepared Mgf SPNMS
Globule size (Dnm), zeta potential, and self-emulsification
time (Temul)
The value ofDnm, ranging between 15 and 60 nm, assures the
nanomicellar nature of the developed formulations.
Emulgents enable to reduce the interfacial tension and stabi-
lize the globules, thus resulting in the formation of smaller
globules [60]. Further, nanometeric size range of globules
can be ascribed to the ability of the cosolvent to facilitate the
efficient emulsification and fluidization of the oil-surfactant
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Fig. 1 a Cumulative in vitro drug release profile of Mgf from various
formulations prepared as per the I-Optimal mixture design. b In vitro drug
release profile of optimized SPNMS and drug suspension of Mgf, values
expressed in mean ± SD (n = 6). c Design space overlay plot for opti-
mized SPNMS. d TEM images of SPNMS. Time- and dose-dependent
percentage cell viability by different concentrations of Mgf, B-SPNMS
(blank SPNMS), and M-SPNMS (Mgf-loaded SPNMS) at e–f 24 h, g–h
48 h, and i–j 72 h in MCF-7 and MDA-MB-231 cell lines. Data shown
are mean ± SD from three independent experiments
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blend [61]. Zeta potential was found to range between − 20
and − 29 mV, indicating the stability of the developed formu-
lation. It is reported in literature that the negative charge in
nanomicelles is due to the presence of free fatty acids on oil
droplets [62]. Temul values were observed to range within 22 to
64 s. Less values of Temul indicated the tendency of the for-
mulation to emulsify faster in order to produce transparent
nanoemulsion [53].
In vitro drug release studies
From the dissolution studies, nearly complete drug release (>
90%) was observed for all formulations resulted within 1 h
indicating faster Mgf release from SPNMS (Fig. 2a). The inset
in the figure is a clear testimony to more than 80% of Mgf
release in 15 min. Also, significant improvement (i.e., about
fivefolds) in the dissolution rate was observed vis-à-vis free
Mgf suspension (p < 0.001) (Fig. 2b). MDTwas found to vary
between 3 and 18min, while %DEwas found to vary between
22 and 34%.
Permeability studies
Everted gut sac studies indicated that the values of intestinal
permeability varied from 59 to 88% for all the developed
SPNMS of Mgf. The results are in consonance with literature
reports, where the authors also report the increase in mem-
brane permeability with self nano-emulsifying globules
[63–65].
Search for the optimum formulation and validation
of QbD
Selected CQAs were traded-off to arrive at the optimum for-
mulation and to achieve requisite objectives, i.e., smallerDnm,
minimal Temul, highest Rel15min, and maximum Perm45min.
Therefore, the selection criteria were finalized to search the
optimized formulation with Dnm < 50 nm, zeta potential <−
30, Temul < 1 min, Rel15min > 80%, DE > 20%, MDT > 7 min,
and Perm45min > 70%. Numerical desirability methodology
was adopted for identifying the optimum formulation, where
all the CQAs exhibited the value of desirability function close
to unity. Figure 2c portrays the optimized SPNMS of Mgf,
demarcated in the design space overlay plot. The optimized
formulation contained Phospholipid 90G (312 mg), vitamin E
TPGS (294 mg), and PEG 200 (393 mg), with the values of
CQAs as Dnm of 25 nm, zeta potential of − 25, Temul of 39 s,
Rel15min of 82%, DE of 26%,MDTof 10, and Perm45min 73%,
respectively. The TEM analysis of the optimized formulation
(Fig. 2d) evidently indicated spherical globules of the SPNMS
formed with a mean size of about 15 nm.
Cell line results
Cell viability assay
Various percentage cell viability plots portray that Mgf-
SPNMS show the higher toxicity towards MCF-7, suggesting
faster onset of action in 24 h, whereas hardly any cell death
was observed for MDA-MB-231 cells at the same time-point.
Maximum cell death for MDA-MB-231 cells at similar con-
centration ranges was observed at 72 h. Also, IC50 value for
MCF-7 cells was found to be 37.56, 22.65, and 4.37 nM at 24,
48, and 72 h, respectively, while negligible cell death was
observed at 24 h and a slightly higher IC50, i.e., 52.13 and
45.39 nM, was observed with MDA-MB-231 at 48 and 72 h,
respectively (Fig. 2e–j). This could be attributed to the higher
accumulation of Mgf-SPNMS in MCF-7 than MDA-MB-231
cells, which is known to express P-gp efflux transporters. The
higher expression of P-gp receptors on MDA-MB-231 might
be responsible for lower accumulation of Mgf-SPNMS in
these cells [66]. Moreover, triple negative MDA-MB-231
cells, which bear an aggressive phenotype, usually respond
less favorably to the compounds than the less aggressive, es-
trogen receptor positive, MCF-7 breast cancer cells [67, 68].
Qualitative and quantitative cellular uptake
On investigating the cellular uptake onMCF-7 andMDA-MB-
231 cells, it was observed that Rh-123-SPNMS started migrat-
ing within both the cells in 15 min. Qualitative analysis made
through the images were processed through Zen Pro 2012,
displaying the fluorescent images of Rh-123-SPNMS uptake
at various time-points (Fig. 3a, d). The corresponding overlay
histograms (Fig. 3b, e), generated after the data were analyzed
using the Flowing software, further corroborated the substan-
tial cellular uptake of Rh-123-SPNMS at the same time points,
i.e., 15, 30 min, and 1, 2, and 4 h. Through the qualitative and
quantitative observations made, intensity of fluorescence was
observed to be much higher for MCF-7 cells than for MDA-
MB-231 cells (p < 0.05) (Fig. 3c, f), suggesting that the
SPNMS encountered less hindrance with the former cell lines.
Therefore, one could conclude and correlate the cellular
viability and uptake results, in which higher and quicker cel-
lular uptake of the formulation is the indicative of the lower
IC50 values obtained for both the cell lines. Also, it is reported
that the higher cellular uptake of the SPNMS is owing to the
presence of surfactants, attributing to the enhancement of the
permeability and could change the cell integrity [69, 70].
Fig. 2 3D-Response surface plots showing the influence of Phospholipid
90G, Vitamin E TPGS, and PEG 200 on the CQAs, viz. a Globule size
(Dnm), b percent drug release in 15 min (Rel15min), c mean dissolution
time (MDT), d dissolution efficiency (DE), e emulsification time (Temul), f
permeability in 45 min (Perm45min), and g zeta potential
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P-gp efflux assay
The P-gp efflux assay revealed that at 4 °C, there was no
evidence of active transport, as the MDR and BCRP trans-
porters were inactive, leading to higher accumulation of dyes
inside the cells, as can be clearly evident from the fluorescence
intensity (Fig. 4a). On the other hand, incubation at 37 °C
showed active efflux of both dyes (Rh-123 and DiOC2); how-
ever, in the presence of vinblastine, which blocks both the
MRP2 and BCRP transporters, lead eventually to higher fluo-
rescence intensity without any efflux [71]. Relatively less ef-
flux of Rh-123 and DiOC2 in the presence of SPNMS could
be attributed to the excipients like vitamin E TPGS [72] and
PEG [73, 74], which act as the P-gp efflux inhibitors, which is
in total agreement with the literature reports. In this context,
SPNMS would be an adept carrier for delivery of Mgf, which
is a P-gp substrate [75], facilitate its accumulation in cancer
cells by weakening its P-gp mediated efflux.
Intestinal permeation study of Mgf
Figure 4b shows that Rh-123 dye, of its own, does not permeate
through the intestine, as it has a tendency to get effluxed by P-gp
receptors. However, using optimized Rh-123 SPNMS (Fig. 4c),
the fluorescent microvilli of the intestine were observed, indicat-
ing the penetration of the prepared formulation, majorly due to
the droplets being formed in the nanometric size range.
Consequently, the outcome from the CLSM study corroborates
improved intestinal permeation with SPNMS, ostensibly owing
Fig. 3 a and dQualitative analysis indicated the increased cellular uptake
with the increase in the Rh-123 intensity for MCF-7 and MDA-MB-231,
respectively. b and e Flow cytometry histogram overlays for MCF-7 and
MDA-MB-231 cells of Rh-123 SPNMS following control (untreated
cells), 15 min, 30 min, 1 h, 2 h, and 4 h incubation at 37 °C. c and f
Fluorescence intensity plotted vs. time also corroborated the cellular up-
take for MCF-7 and MDA-MB-231, respectively
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to the formation of nano-micelles and the presence of vitamin E
TPGS [72] and PEG to act as P-gp inhibitors [74].
In situ intestinal perfusion studies
These studies explore the absorption and permeation behavior of
a drug, when administered as an oral formulation [24]. With
SPNMS, enhanced values of absorptivity and permeability pa-
rameters of Mgf were observed vis-à-vis pure bioactive. As is
evident from Fig. 5a, Mgf SPNMS showed significantly escala-
tion in the values of (p< 0.001) absorption number (An) by 8.12-
fold and 3.54-fold, vis-à-vis pureMgf alone, and with verapamil,
respectively. The amount of drug transferred across the GI tract,
where Mgf SPNMS exhibited distinct superiority over free bio-
active, indicated enhanced drug absorption characteristics [76].
Verapamil, being a potent P-gp inhibitor, was able to im-
prove the permeation and absorption parameters, but only up
to a limited extent [77, 78]. Further, a significant increase
(p < 0.01) in the values of fraction drug absorbed (Fa) was
also observed for Mgf SPNMS (i.e., 4.06-fold), and Mgf ad-
ministered with verapamil (i.e., 3.64-fold) vis-à-vis pure Mgf.
The aforementioned results indicated notable augmentation in
the absorption potential of Mgf SPNMS, ostensibly due to
transport of bioactive through lymphatic pathways via circum-
navigation of its first-pass effect in the liver [24, 79, 80].
Similarly, in case of permeability parameters, the values of
effective permeability (Peff) also showed significant, i.e., nearly
6.56-fold and 2.57-fold improvement with SPNMS of Mgf and
Mgf-verapamil (p < 0.001 each) vis-à-vis pure Mgf, respective-
ly. Likewise, significant increase (p < 0.001) in the correspond-
ing values of wall permeability (Pwall) was also observed by
about 6.88-fold and 4.11-fold. The greater values of Peff and
Pwall delineate increase in the permeability and uptake charac-
teristics of the optimized formulation, plausibly ascribed to im-
proved permeability and decreased efflux due to the incorpora-
tion of emulsifying excipient in the formulations [81, 82].
In vivo pharmacokinetic studies
Following per oral administration of Mgf SPNMS and pure
Mgf, plasma levels were monitored in rat at the designated
time-points. Thus, the pharmacokinetic profile (Fig. 5b) shows
Fig. 3 (continued)
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considerable difference in the plasma concentrations for Mgf
SPNMS vis-à-vis pure Mgf (dose equivalent to 30 mg/kg [39])
at all the time-points studied (p < 0.001). Furthermore, a linear
decline in the post-Tmax log concentration-time profile showed
that the drug profile follows 2-CBM kinetics [19]. Table 1
shows various calculated pharmacokinetic parameters for Mgf
and Mgf SPNMS with statistically significant (p < 0.001) dif-
ference among all the parameters as estimated in rats treated
with pure plant bioactive versus its SPNMS formulation.
Nearly 4.22- and 2.96-fold increase in the magnitude of
Cmax and AUC was noted on comparing with pure drug
(p < 0.001), respectively. Moreover, there was 2.65-fold re-
duction in Tmax vis-à-vis pure Mgf (p < 0.001), thus corrobo-
rating quite faster onset of action owing to improvement in
absorption rate. Besides, maximal variation was observed in
the values of Ka, indicating enhanced oral drug absorption of
Mgf SPNMS revealing nearly 3.59-fold increase in Ka over
plain Mgf (p < 0.001). By and large, the pharmacokinetic
Fig. 4 a Relatively higher fluorescence intensity index indicates
inhibition of MDRI and BCRP transporters maximally by Mgf-SPNMS
loaded with Rh-123 and DiOC2 dye, respectively. b Shows no migration
of Rh-123 dye into the intestine. c Rh-123 loaded SPNMS has migrated
to microvilli of intestine, indicating its better absorption. d
Histopathological findings were examined on comparing with the (a)
untreated rat after administering saline solution, (b) plain Mgf, (c) blank
SPNMS formulation, and (d) Mgf SPNMS. (1) Kidney (a, b, c, d): glo-
meruli, tubules, and blood vessels are within normal limits. (2) Heart (a, b,
c, d): endocardium, epicardium, and myocardium do not show any sig-
nificant changes. (3) Pancreas (a, b, c, d): pancreatic acini and islets do not
show any significant changes. (4) Brain (a, b, c, d): the meninges, cerebral
cortex, white matter, cerebellum, hippocampus, and choroid plexus are
within normal limits. (5) Lung (a, b, c, d): the pleura, parenchyma, and the
interstitium do not show any significant changes. (6) Small intestine (a, b,
c, d): ileum shows normal villi and the brush borders are maintained. No
other significant changes are observed. (7). Large intestine (a, b, c, d):
mucosa, submucosa, muscularis propria, and serosa are within normal
limits. (8). Spleen (a, b, c, d): the splenic red and white pulp does not
show any significant changes and are within normal limits. (9) Liver (a, b,
c, d): the portal tracts, central vein, and sinusoids do not show any sig-
nificant changes. (10) Stomach (a, b, c, d): mucosa, submucosa,
muscularis propria, and serosa do not show any significant changes.
Pictures of whole blood extracted from rats after various treatments e
control, f Mgf, and g Mgf SPNMS
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studies in rats ratified the superiority of the formulated Mgf
SPNMS in enhancing oral absorption of Mgf.
In vivo toxicity studies
Figure 4d portrays no histopathological change(s) in all the
vital organs, indicating that all the three treatments, i.e., Mgf
(Fig. 4d (b)), blank (Fig. 4d (c)), and Mgf SPNMS (Fig. 4d
(d)) were found to be quite biosafe as that of control (Fig. 4d
(a)). Further, all the treated groups, i.e., Mgf, blank SPNMS,
and Mgf-loaded SPNMS showed insignificant (p > 0.05)
pathological changes vis-a-vis the control group.
The whole blood count analysis revealed that all the three
treatments were not significantly (p > 0.05) affecting the white
blood cells (WBC), red blood cells (RBC), hemoglobin
(HGB), hematocrit (HCT), and platelet (PLT) count.
Treatments with Mgf, blank SPNMS, and Mgf SPNMS de-
creased the values of WBC, RBC, HGB, and PLT, but the
change was not found to be that profound (Table 2). The slides
of the blood sample were prepared and observed under upright
light microscope. Results showed no morphological changes
in the shape of RBC, when treated with any of the formulation
on comparing with the control (Fig. 4e–g). As it is evident
from the histopathology studies (Fig. 4d) that the Mgf alone,
blank SPNMS and Mgf SPNMS do not show any sign of
toxicity on all the vital organs. The results are in accordance
with the literature reports where the blank nanomicelles have
shown practically no toxicity [83, 84].
Conclusions
In the current studies, SPNMS ofMgf were systematically and
successfully developed, which finally composed of
Phospholipid 90G, vitamin E TPGS, and PEG 200. Apart
from its surfactant like property, vitamin E TPGS was incor-
porated in the formulation to prevent any possible oxidation of
Mgf, and its level was kept as constant throughout the study.
In this piece of work, in vitro, in situ, and in vivo studies
carried out on the formulations proved these nanostructures to
be highly superior to pure bioactive. The toxicity studies con-
firmed that the ingredients employed in the formulations were
quite biosafe. Therefore, it can be concluded that SPNMSwith
high drug pay-load possess tremendous promise to augment
oral bioavailability of Mgf and several other agents of BCS
class IV marked with poor solubility and permeability charac-
teristics like Mgf.
Fig. 5 a Percent increase in permeability and absorption parameters of
Mgf calculated after administering optimized Mgf SPNMS, Mgf
administered with verapamil vis-à-vis pure Mgf. b Mean plasma
concentration-time curve of Mgf and Mgf SPNMS equivalent to 30 mg/
mL (n = 6), respectively; mean value of ± SD
Table 1 Pharmacokinetic parameters obtained from in vivo plasma level studies in rat following oral administration of Mgf and its SPNMS
Treatment formulations Pharmacokinetic parameters
Cmax (ng.h
−1) AUClast (h × ng.ml
−1) Cmax/AUC (h
−1) Ka (h−1) Tmax (h) MRT (h) Cl (mL.h
−1)
Mgf 297.14 ± 56.36 213.38 ± 25.13 0.098 0.32 ± 0.09 3.08 ± 0.18 8.16 ± 1.73 2543.44 ± 453.42
Mgf SPNMS 1254.62 ± 182.15 8962.15 ± 357.18 0.017 1.15 ± 0.25 1.43 ± 0.24 14.19 ± 1.65 1245.72 ± 267.13
All the data represented as mean ± SD (n = 3)
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